All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
Antegren
National Institutes of Health
Topic mentions per year
Topic mentions per year
1998-2010
0
1
2
3
1998
2010
Related topics
Related topics
1 relation
Broader (1)
natalizumab
Related mentions per year
Related mentions per year
1992-2018
1990
2000
2010
2020
Antegren
natalizumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
Thomas Vollmer
,
Julie Phillips
,
+4 authors
John S. Grundy
Multiple sclerosis
2004
In this open-label drug-interaction trial, we studied 38 patients with relapsing-remitting multiple sclerosis (MS) who received 3…
(More)
Is this relevant?
2004
2004
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
Paul O'Connor
,
A. Goodman
,
+6 authors
L A Stone
Neurology
2004
BACKGROUND Relapses in multiple sclerosis (MS) can cause significant neurologic disability. Natalizumab (Antegren) is a humanized…
(More)
Is this relevant?
Review
2004
Review
2004
Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Drugs in R&D
2004
Natalizumab [AN 100226, anti-alpha4 integrin monoclonal antibody, Antegren] is a humanised monoclonal antibody that blocks…
(More)
Is this relevant?
Review
2004
Review
2004
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Richard A. Rudick
,
Alfred W. Sandrock
Expert review of neurotherapeutics
2004
Natalizumab (Antegren, Elan Corp. plc.; Biogen Idec.) is the first alpha4-integrin antagonist in the class of selective adhesion…
(More)
Is this relevant?
Review
2003
Review
2003
[Diagnosis and treatment of multiple sclerosis. Update, 2003].
Sven Jarius
,
R. Hohlfeld
,
Raymond Voltz
MMW Fortschritte der Medizin
2003
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. The etiology of MS is not yet…
(More)
Is this relevant?
2002
2002
[Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis].
Tania Kuempfel
,
Nader Heydari
,
R. Hohlfeld
Der Nervenarzt
2002
Antegren (Natalizumab) is a humanized monoclonal antibody directed against alpha 4-integrin. This antibody binds to the alpha 4…
(More)
Is this relevant?
2002
2002
Antegren (Natalizumab)Ein viel versprechender neuer Ansatz für die Therapie der Multiplen Sklerose
Tania Kuempfel
,
Nader Heydari
,
R. Hohlfeld
Der Nervenarzt
2002
Antegren (Natalizumab) ist ein “humanisierter” monoklonaler Antikörper, der an die α4-Untereinheit von α4β1-Integrin (VLA-4) und…
(More)
Is this relevant?
1999
1999
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
Niall Tubridy
,
Patrice Behan
,
+12 authors
D. H. Miller
Neurology
1999
OBJECTIVE To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or…
(More)
Is this relevant?
1998
1998
Antegren Athena Neurosciences Inc.
Manuel Elices
IDrugs : the investigational drugs journal
1998
AN-100226 (Antegren), a humanized monoclonal antibody (MAb) directed against the alpha4beta1 integrin (VLA-4) expressed on…
(More)
Is this relevant?
Review
1998
Review
1998
Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents.
K. C. Lin
,
Alberto Castro
Current opinion in chemical biology
1998
In recent years antagonists of very late antigen-4 (VLA4, also known as integrin alpha(4) beta(1)) have shown great promise in…
(More)
Is this relevant?